of active comparators and appropriate sham alternatives. Further, short-duration RCTs cannot provide adequate prognostic information when applied to a complex disease such as OA, in which pathophysiologic processes are slowly progressive over decades. We focused on management options that are available in the US and, for pharmacologic therapies, we additionally focused on agents that are available in pharmaceutical-grade formulations, thus eliminating most nutraceuticals. We limited our review